Global Blood Sugar Monitor Market Size By Type (Glucose Oxidase, Glucose Dehydrogenase), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Blood Sugar Monitor Market was valued at USD 14.6 billion in 2023 and is projected to reach USD 28.3 billion by 2031, growing at a CAGR of 8.7% during the forecast period (2023–2031). The growth of this market is driven by the rising prevalence of diabetes globally, increasing awareness about glucose monitoring, and advancements in digital health technologies. As the global diabetic population continues to rise—especially in aging and urbanizing regions—continuous glucose monitoring (CGM) and self-monitoring blood glucose (SMBG) devices are becoming critical tools for disease management and prevention of complications.

Drivers:

1. Rising Global Diabetes Prevalence:

With over 530 million people affected by diabetes globally as of 2023, the need for efficient and real-time glucose monitoring devices has surged. This trend is expected to continue, driven by lifestyle factors such as poor diet and sedentary habits.

2. Increasing Adoption of Continuous Glucose Monitors (CGMs):

CGMs offer real-time insights and predictive analytics, making them increasingly popular among patients and healthcare providers seeking proactive management of diabetes.

3. Government Initiatives and Health Campaigns:

Public health policies and awareness campaigns are actively promoting early diabetes diagnosis and continuous monitoring, thereby fueling market growth.

Restraints:

1. High Cost of Advanced Monitoring Devices:

Despite their effectiveness, CGMs and other advanced monitoring systems are cost-prohibitive, especially in low-income and developing countries.

2. Limited Access to Healthcare Infrastructure in Rural Regions:

In many emerging markets, the penetration of medical technologies is limited by inadequate infrastructure and healthcare services.

Opportunity:

1. Integration with Mobile Health Platforms and IoT:

The emergence of smart wearables and mobile health apps presents a significant opportunity for personalized and remote diabetes management.

2. Expansion in Emerging Economies:

Countries in Asia-Pacific, Latin America, and Africa present untapped growth potential, particularly as awareness and income levels rise.

Market by System Type Insights:

The Continuous Glucose Monitoring (CGM) segment held the largest market share in 2023. CGMs are increasingly preferred due to their real-time data capabilities, reduced need for finger-prick tests, and compatibility with insulin delivery systems. The Self-Monitoring Blood Glucose (SMBG) segment remains significant, especially among type 2 diabetic patients managing their condition with diet or oral medications.

Market by End-Use Insights:

Hospitals and Clinics dominated the market in 2023 due to the rising number of hospital-based diagnoses and glucose monitoring in inpatient settings. However, the homecare segment is expected to grow rapidly, driven by the increasing trend of self-monitoring and remote patient management, particularly among elderly populations and in rural areas.

Market by Regional Insights:

North America led the global blood sugar monitor market in 2023, supported by high diabetes prevalence, strong reimbursement policies, and advanced healthcare infrastructure. The Asia-Pacific region is anticipated to register the fastest growth during the forecast period due to a large diabetic population base, rising health awareness, and increasing adoption of digital health tools.

Competitive Scenario:

Leading companies in the Global Blood Sugar Monitor Market include Abbott Laboratories, Dexcom Inc., F. Hoffmann-La Roche Ltd., Medtronic plc, Ascensia Diabetes Care, Senseonics Holdings, Inc., Ypsomed AG, ACON Laboratories Inc., LifeScan Inc., and i-SENS Inc. These players are focusing on product innovation, technological integration, and geographic expansion. Notable developments include:

In 2024, Abbott launched an upgraded FreeStyle Libre CGM with extended wear duration and improved smartphone connectivity.

Dexcom introduced a compact and implantable glucose sensor in 2023 aimed at pediatric and elderly diabetic patients.

Senseonics gained FDA approval for its 180-day implantable CGM system in early 2025, expanding its U.S. market footprint.

Scope of Work – Global Blood Sugar Monitor Market

Report Metric Details

Market Size (2023) USD 14.6 billion

Projected Market Size (2031) USD 28.3 billion

CAGR (2023–2031) 8.7%

Market Segments By System Type (CGM, SMBG), By End-Use (Hospitals, Homecare, Clinics)

Growth Drivers Rising diabetes prevalence, CGM adoption, supportive health policies

Opportunities mHealth integration, expansion in emerging economies

Key Market Developments:

2023: Abbott introduced an advanced AI-integrated CGM platform for enhanced analytics an